RVL Pharmaceuticals (FRA:O1P) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. RVL Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.00.

RVL Pharmaceuticals's long-term debt to total assets ratio declined from Jun. 2022 (0.35) to Jun. 2023 (0.00). It may suggest that RVL Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

RVL Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for RVL Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals LT-Debt-to-Total-Asset Chart

RVL Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.34

0.59

0.31

0.43

RVL Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.35	0.36	0.43	0.48	-

RVL Pharmaceuticals LT-Debt-to-Total-Asset Calculation

RVL Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	52.498	/	121.313
	=	0.43

RVL Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )	/	Total Assets (Q: Jun. 2023 )
	=	0.177	/	78.828
	=	0.00

RVL Pharmaceuticals (FRA:O1P) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

RVL Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

RVL Pharmaceuticals (FRA:O1P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (FRA:O1P) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

RVLPQ:USA

Address

400 Crossing Boulevard, Bridgewater, NJ, USA, 08807

Website

https://www.rvlpharma.com

RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

RVL Pharmaceuticals (FRA:O1P) Headlines

No Headlines